Blinatumomab Granted FDA Approval for MRD+ ALL

Blinatumomab (Blincyto) has been granted an accelerated approval by the FDA for the treatment of patients with B-cell precursor acute lymphoblastic leukemia who are in remission but still have minimal residual disease.

Read full article (External website)

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply